109186 ⎘
Structure or type of the nucleic acid; Chemical structure; Spatial arrangement of the modifications Gapmers, i.e. of the type ===---===
PHARMACEUTICAL COMPOSITION FOR TREATING SPINOCEREBELLAR ATAXIA
#2COMPOSITIONS, METHODS, AND KITS RELATING TO THERAPEUTICS FOR THE MODULATION OF SEL1L-HRD1 ERAD ACTIVITY AND FUNCTION
#3OLIGONUCLEOTIDES
#4Compositions and Methods for Treating and Preventing Prekallikrein-Associated Conditions
#5Compositions for Modulating C9ORF72 Expression
#6COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#7ANTI-CANCER TGFB2 AGENTS WITH IMMUNOTHERAPEUTICS
#8Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations
#9Compounds and Methods for Modulating UBE3A-ATS
#10RUNX1 MODULATORS
#11COMPOSITIONS AND METHODS FOR TREATING MYOPATHY
#12Compounds and Methods for Reducing ATXN3 Expression
#13COMPOSITIONS AND METHODS TO MODULATE TUMOR MICROENVIRONMENT ASSOCIATED LONG NONCODING RNAS
#14POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#15TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
#16ANTISENSE OLIGONUCLEOTIDE TARGETING TDP-43 MRNA OR PRE-MRNA
#17Oral Delivery of Antisense Conjugates Targeting PCSK9
#18OLIGONUCLEOTIDES FOR MODULATING REGULATORY T CELL MEDIATED IMMUNOSUPPRESSION
#19ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS
#20METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A)
#21COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#22HYBRID OLIGONUCLEOTIDES
#23EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA
#24ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF
#25Compositions and Methods for Modulating Complement Factor B Expression
#26COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER
#27OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#28COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
#29OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#30COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH PATHOGENIC FUS VARIANTS
#31THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF
#32Selective Antisense Compounds and Uses Thereof
#33MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS
#34Linkage Modified Oligomeric Compounds and Uses Thereof
#35Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#36METHODS OF TREATING X-LINKED GENETIC DISEASES
#37CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#38COMPOUNDS AND METHODS FOR REDUCING PCDH19 EXPRESSION
#39BBB-CROSSING LIPID LIGAND OF HETERO NUCLEIC ACID
#40SUSTAINED RELEASE NUCLEIC ACID FORMULATIONS FOR TREATMENT OF PERIPHERAL NERVE DEMYELINATION
#41Compounds and Methods for Reducing KCNT1 Expression
#42Conjugated Antisense Compounds for Use in Therapy
#43NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
#44Compounds and Methods for Reducing LRRK2 Expression
#45COMPOUNDS AND METHODS FOR MODULATING ATXN1
#46MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
#47Compounds and Methods for Modulating UBE3A-ATS
#48COMPOSITIONS FOR TARGETING FLI-1 AND METHODS OF USE THEREOF
#49COMPOSITIONS AND METHODS RELATED TO MULTIPLE MYELOMA-ASSOCIATED LONG NONCODING RNAS
#50ANTI-CANCER AGENTS
#51COMPOUNDS AND METHODS FOR MODULATING SCN2A
#52Selective Antisense Compounds and Uses Thereof
#53MSI2 AS A THERAPEUTIC TARGET FOR THE TREATMENT OF MYOTONIC DYSTROPHY
#54Linkage Modified Oligomeric Compounds
#55MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#56COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF
#57Oligonucleotides
#58ANTISENSE NUCLEIC ACID CAPABLE OF INHIBITING BIOSYNTHESIS OF CHONDROITIN SULFATE
#59SYF2 ANTISENSE OLIGONUCLEOTIDES
#60Selective Reduction of Allelic Variants
#61POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#62METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#63ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
#64METHODS OF TREATING CANCER AND/OR ENHANCING SENSITIVITY TO CANCER TREATMENT BY INCREASING TUMOR MUTATION BURDEN OR TUMOR INDELS
#65HETERONUCLEIC ACID INCLUDING 2'-MODIFIED NUCLEOSIDE
#66THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETS
#67MODULATORS OF MALAT1 EXPRESSION
#68Composition and Methods for Modulating Nuclear Enriched Abundant Transcript 1 to Treat Cognitive Impairment
#69MODULATION OF ALPHA SYNUCLEIN EXPRESSION
#70METHOD FOR REDUCING HEPATIC TRIGLYCERIDES
#71COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#72COMBINATIONS WITH MODULATORS OF PNPLA3 EXPRESSION
#73OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#74COMPOUNDS FOR INHIBITION OF IL-1BETA EXPRESSION
#75MODULATING THE CELLULAR STRESS RESPONSE
#76COMPOUNDS FOR INHIBITING AMANZI
#77EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6
#78METHODS OF TREATMENT OF SCN2A-RELATED DISORDERS
#79PIKFYVE ANTISENSE OLIGONUCLEOTIDES
#80COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTIONS
#81Modified Oligonucleotides and Methods of Use
#82COMPOSITIONS AND METHODS FOR MODULATING NEURONAL EXCITABILITY AND MOTOR BEHAVIOR
#83ACVR1R206H ALLELE-SPECIFIC THERAPY AND USES THEREOF FOR TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
#84ANGELMAN SYNDROME ANTISENSE TREATMENT
#85MODULATORS OF APOL1 EXPRESSION
#86THERAPEUTIC OLIGONUCLEOTIDES
#87OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#88INHIBIN SUBUNIT BETA E (INHBE) MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF
#89OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
#90COMPOSITIONS AND METHODS OF MODULATING LONG NONCODING TRANSCRIPTS ASSOCIATED WITH ARDS INDUCED PULMONARY FIBROSIS
#91ANTISENSE OLIGONUCLEOTIDE TARGETING ATN1 MRNA OR PRE-MRNA
#92METHODS OF SILENCING EXPRESSION OF GENES AND USES THEREOF
#93METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
#94Oligonucleotides for Modulating Synaptogyrin-3 Expression
#95OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5
#96RNAi TARGETING PPP2R5D MISSENSE MUTATIONS FOR TREATMENT OF JORDAN’S SYNDROME
#97RNAi TARGETING KIF1A MISSENSE MUTATIONS FOR TREATMENT OF KIF1A ASSOCIATED NEUROLOGICAL DISORDER
#98PREVENTIVE OR THERAPEUTIC AGENT FOR BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY
#99COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION
#100Compounds and Methods for Reducing ATXN2 Expression
#101COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#102Oligonucleotides
#103OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURES
#104GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#105Selective Antisense Compounds and Uses Thereof
#106Compounds and methods for reducing LRRK2 expression
#107ANTISENSE OLIGONUCLEOTIDE THERAPY FOR H3.3 K27M DIFFUSE MIDLINE GLIOMAS
#108ANTISENSE INHIBITORS OF MIR17HG PRE-RNA AS THERAPEUTIC AGENTS IN CANCER
#109Compositions and methods for modulating apolipoprotein (a) expression
#110TREATMENT FOR TYROSINE DEGRADATION-ASSOCIATED DISORDERS
#111Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
#112THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF
#113ANTISENSE OLIGONUCLEOTIDES TARGETING UNC13A
#114MODULATORS OF ENaC EXPRESSION
#115MODULATION OF PREKALLIKREIN (PKK) EXPRESSION
#116Antisense oligonucleotide targeting ATN1 mRNA or pre-mRNA
#117COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION
#118COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION
#119COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#120ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION
#121Selective Antisense Compounds and Uses Thereof
#122ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES
#123NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES
#124Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides
#125OLIGONUCLEOTIDES
#126Compounds and Methods for Modulating GFAP
#127COMPOUNDS FOR REDUCING PTBP1 EXPRESSION
#128MODULATION OF COASY EXPRESSION
#129ANTISENSE OLIGONUCLEOTIDE TARGETING CAV3.1 GENE AND USES THEREOF
#130NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS
#131CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#132COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
#133Heteronucleic acid containing scpBNA or AmNA
#134MODULATING APOLIPOPROTEIN (A) EXPRESSION
#135THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETS
#136COMPOUNDS AND METHODS FOR MODULATING PLP1
#137Compositions for Modulating C9ORF72 Expression
#138ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSION
#139METHODS FOR MODULATING FMR1 EXPRESSION
#140Conjugated Antisense Compounds for Use in Therapy
#141METHOD OF TREATING FATTY LIVER DISEASE
#142CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#143OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#144MODULATION OF GYS1 EXPRESSION
#145Selective Antisense Compounds and Uses Thereof
#146ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF CORNEAL DYSTROPHIES
#147MODULATION OF TRANSTHYRETIN EXPRESSION
#148MODIFIED HETERO NUCLEIC ACIDS
#149POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#150Compounds and methods for modulating SCN2A
#151MODULATION OF AAV-BASED GENE EXPRESSION
#152COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#153ANTISENSE OLIGONUCLEOTIDES INCREASING FOXG1 EXPRESSION
#154OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#155ANTISENSE OLIGOMERS TARGETING PCSK9
#156COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#157ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9
#158Compounds and methods for modulating ATXN1
#159POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS
#160ANTISENSE COMPOUNDS
#161OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUS
#162COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#163OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
#164COMPOUNDS AND METHODS FOR MODULATING SCN2A
#165NUCLEIC ACID DUPLEXES
#166COMPOUNDS FOR MODULATING CHMP7
#167LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#168OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES
#169UMLILO ANTISENSE TRANSCRIPTION INHIBITORS
#170MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF
#171TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY
#172Compositions and Methods Targeting circ2082 for the Treatment of Cancer
#173Human XIST Antisense Oligonucleotides for X Reactivation Therapy
#174COMBINATION
#175COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#176COMPOUNDS AND METHODS FOR REDUCING APOE EXPRESSION
#177OLIGONUCLEOTIDES
#178TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK)
#179Angelman syndrome antisense treatment
#180OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
#181COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
#182Compositions for modulating tau expression
#183Targeting enhancer RNAs for the treatment of primary brain tumors
#184Modulators of PCSK9 Expression
#185COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME
#186Oligonucleotides for inducing paternal UBE3A expression
#187NUCLEIC ACID COMPLEX
#188Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#189COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF
#190THERAPEUTICS FOR SYNGAP HAPLOINSUFFICIENCY
#191Modulators of APOL1 expression
#192MODULATION OF FACTOR 11 EXPRESSION
#193COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
#194Guanosine Analogues for Use in Therapeutics Polynucleotides
#195METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#196USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#197USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#198Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#199COMPOSITIONS AND METHODS OF INHIBITING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
#200COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#201COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PREKALLIKREIN-ASSOCIATED CONDITIONS
#202MODULATORS OF GROWTH HORMONE RECEPTOR
#203ANTISENSE OLIGONUCLEOTIDE OF ATN1
#204COMPOUNDS AND METHODS FOR MODULATING KCNQ2
#205USE OF COPS3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#206Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#207COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#208USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#209MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY
#210Compounds and methods for reducing LRRK2 expression
#211Selective Antisense Compounds and Uses Thereof
#212Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#213Compositions for Modulating C9ORF72 Expression
#214Angleman syndrome antisense treatment
#215COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES
#216ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS
#217ANTISENSE OLIGONUCLEOTIDE TARGETING LINC00518 FOR TREATING MELANOMA
#218Methods and compositions for reducing pathogenic isoforms
#219TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
#220Compositions and methods for modulating complement factor B expression
#221COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#222Antisense Oligonucleotides Targeting ATXN3
#223Modulators of diacyglycerol acyltransferase 2 (DGAT2)
#224METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXAPNSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY
#225COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#226Modulation of huntingtin expression
#227Compounds and methods for modulating factor XII
#228EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA
#229Selective antisense compounds and uses thereof
#230PIKFYVE antisense oligonucleotides
#231COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION
#232Compounds and methods for modulating UBE3A-ATS
#233THERAPEUTIC OLIGONUCLEOTIDE METHODS
#234Selective reduction of allelic variants
#235COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#236PPM1A INHIBITORS AND METHODS OF USING SAME
#237ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
#238NUCLEIC ACID THAT INHIBITS EXPRESSION OF MEX3B GENE, MEX3B GENE EXPRESSION INHIBITING AGENT, METHOD FOR INHIBITING MEX3B GENE EXPRESSION, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY MEX3B GENE EXPRESSION
#239COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION
#240COMPOUNDS AND METHODS FOR REDUCING SNCA EXPRESSION
#241DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOF
#242Compounds and methods for modulating ATXN1
#243METHOD OF MODULATING ADIPOSITY
#244MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER
#245COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#246UBE3A ANTISENSE THERAPEUTICS
#247COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#248METHOD FOR REDUCING TOXICITY OF ANTISENSE NUCLEIC ACIDS
#249Enhanced oligonucleotides for inhibiting RTEL1 expression
#250Methods and compositions for inhibiting PMP22 expression
#251ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF
#252Modulators of MALAT1 expression
#253COMPOUNDS AND METHODS FOR REDUCING FUS EXPRESSION
#254COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4
#255METHOD FOR INHIBITING INFECTION AND ACTIVATION OF VIRUS
#256ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#257Oral delivery of antisense conjugates targeting PCSK9
#258MODULATION OF TRANSTHYRETIN EXPRESSION
#259MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#260TAU-TARGETING OLIGONUCLEOTIDE GAPMERS
#261COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#262Compositions for modulating Ataxin 2 expression
#263OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#264Linkage modified oligomeric compounds and uses thereof
#265INTRACELLULAR TARGETING OF MOLECULES
#266COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#267COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION
#268Oligonucleotides for modulating Tau expression
#269Antisense Oligonucleotides Targeting ATXN3
#270Modulation of prekallikrein (PKK) expression
#271POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
#272Oligonucleotides for inducing paternal UBE3A expression
#273TAU ANTISENSE OLIGOMERS AND USES THEREOF
#274OPTIMAL PS MODIFICATION PATTERN FOR HETERONUCLEIC ACIDS
#275ANTISENSE OLIGOMERS FOR CONTROLLING CANDIDA ALBICANS INFECTIONS
#276NOVEL TARGET TO TREAT A METABOLIC DISEASE IN AN INDIVIDUAL
#277ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#278Modulation of GYS1 expression
#279Therapeutic compositions for treating pain via multiple targets
#280PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES
#281Antisense Drug Against the Human Intercellular Adhesion Molecule 1 (ICAM-1)
#282NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE
#283Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19
#284Angelman syndrome antisense treatment
#285Method of treating fatty liver disease
#286METHODS AND COMPOSITIONS USING RNA INTERFERENCE AND ANTISENSE OLIGONUCLEOTIDES FOR INHIBITION OF KRAS
#287NOVEL PHOSPHORAMIDITES
#288METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#289MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#290Compounds and methods for reducing ATXN2 expression
#291COMPOSITIONS AND METHODS FOR THE TREATMENT OF KCNT1 RELATED DISORDERS
#292Compounds and methods for modulating PLP1
#293Modulating the cellular stress response
#294ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#295Compositions and their uses directed to huntingtin
#296ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9
#297Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
#298POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#299Antisense oligomers targeting PCSK9
#300OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE